Critical Review: Palvella Therapeutics (PVLA) and Its Rivals

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Palvella Therapeutics to related companies based on the strength of its risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Earnings and Valuation

This table compares Palvella Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Palvella Therapeutics $42.81 million -$41.72 million -27.72
Palvella Therapeutics Competitors $713.66 million $10.27 million -18.80

Palvella Therapeutics’ rivals have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings for Palvella Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palvella Therapeutics 1 0 12 2 3.00
Palvella Therapeutics Competitors 9903 15310 45655 1602 2.54

Palvella Therapeutics presently has a consensus price target of $213.85, indicating a potential upside of 40.25%. As a group, “Biotechnology” companies have a potential upside of 127.14%. Given Palvella Therapeutics’ rivals higher possible upside, analysts clearly believe Palvella Therapeutics has less favorable growth aspects than its rivals.

Volatility and Risk

Palvella Therapeutics has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ rivals have a beta of -1.90, indicating that their average share price is 290% less volatile than the S&P 500.

Profitability

This table compares Palvella Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Palvella Therapeutics N/A -44.44% -36.75%
Palvella Therapeutics Competitors -12,319.70% -407.93% -30.95%

Insider and Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Palvella Therapeutics beats its rivals on 7 of the 13 factors compared.

Palvella Therapeutics Company Profile

(Get Free Report)

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.